Belgian biotech group Galapagos said Tuesday its experimental drug to treat ulcerative colitis had failed to beat placebo in a Phase 2a study, called ORIGIN, and that the company will terminate its clinical development of the candidate, GLPG1205.
“Galapagos will evaluate whether GLPG1205 will be developed in alternative indications,” the company said.
The ulcerative colitis candidate GLPG1205 was well tolerated by patients in the study; however, the study results revealed that GLPG1205 did not statistically significantly differentiate from placebo on (partial) Mayo scores, the company’s release announced.
Additional details about the study will be published later this year.
Ulcerative colitis is a chronic disease of the large intestine, also known as the colon, in which the colon’s lining becomes inflamed and develops ulcers. The disease, the result of an abnormal response by the body’s immune system, can cause symptoms, including abdominal pain, diarrhea, lack of appetite, and fatigue.
Inflammatory bowel diseases (IBD), which include Crohn’s disease and ulcerative colitis, affect as many as 1.4 million Americans, most of whom are diagnosed before age 30, according to the Crohn’s & Colitis Foundation of America.
Filed Under: Drug Discovery
